MediWound (NASDAQ:MDWD – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports.

Avantax Advisory Services Inc. boosted its position in Vericel Co. (NASDAQ:VCEL – Free Report) by 1.7% during the 4th quarter ...

A probable case was defined by an IgM-positive ELISA or the presence of an eschar if blood testing could not be performed. A confirmed case was defined by a positive qPCR test, an IgM-positive ...

Reported positive results from the Expanded Access Protocol (NEXT), reinforcing NexoBrid's clinical and real-world benefits across 29 burn centers in the U.S. The study included 239 patients (215 ...

A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: https://investors.vcel.com.

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its ...

MediWound’s first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...

So as I mentioned, we have two products. The first one on the left is NexoBrid. NexoBrid is a drug for eschar removal for severe burns. In order to remove SCAR in burns, this was horrible image on the ...

Examination revealed edema of the left ear lobe. On the posterior surface there was a small ulcerated papule, covered by a dry black eschar and surrounded by an area of erythema. No adenopathy was ...

Raw wounds erupt into a scaly crust of dead tissue called eschar which, if untreated, can lead to amputation. The use of tranq in Philadelphia has risen in recent years. The city's public health ...